It’s good news for both asthma patients and AstraZeneca after UK drug watchdog NICE saw fit to recommend the drugmaker’s Fasenra (benralizumab) injection as a new option on the NHS in England and Wales for those living with severe forms of the disease.
The decision means that Fasenra becomes the third biological treatment available on routine use for the treatment of severe eosinophilic asthma, alongside GlaxoSmithKline’s Nucala (mepolizumab), recommended in December 2016, and Teva’s Cinqaero (reslizumab), recommended in October 2017.
